Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
CosentyxⓇ FY sales reached USD 5bn¹. Expect mid to high single-digit
growth in 2024 and USD 7bn peak sales
GROWTH
Company overview
Financial review
Conclusions
Appendix
References
Sales evolution
USD m, % cc
US
Ex-US
1,080
447
+21%*
FY USD 5.0bn1
+5%
1,303
Q4 performance benefitted from lower PY base
•
US +17% cc; Ex-US sales +26% cc
Lower PY base in US due to revenue deduction adjustments
•
Launched IV and HS in US
FY 2024: Expect mid to high single-digit growth
562
.
US/EU: HS launch
741
633
Q4 2022
* Benefitting from lower prior year base
Q4 2023
HS - moderate to severe hidradenitis suppurativa in adult population. IV - intravenous.
non-IFRS measures; explanation can be found on page 49 of Condensed Financial Report.
□ NOVARTIS | Reimagining Medicine.
• US: IV launch in adult PsA, AS and nr-axSpA
.
.
China: PsA approved January 2024
Further CosentyxⓇ innovation
3 Ph3 studies ongoing: Giant Cell Arteritis, Polymyalgia Rheumatica,
Rotator Cuff Tendinopathy
Cosentyx
PSA
-
psoriatic arthritis.
AS ankylosing spondylitis.
1. Rounded from USD 4.98bn.
-
nr-axSpA - non-radiographic axial spondyloarthritis.
Constant currencies (cc), core results are
Novartis Q4 Results | January 31, 2024
8View entire presentation